Business Context and Reporting Period
Protalix Biotherapeutics, Inc. filed a Form 8-K Current Report on December 17, 2018. The filing reports on significant clinical trial milestones for the company's lead product candidate, pegunigalsidase alfa (PRX-102), intended for the treatment of Fabry disease.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on operational events regarding clinical trial enrollment.
Material Changes
- BRIDGE Trial: The company announced the completion of patient enrollment for its phase III BRIDGE clinical trial of PRX-102.
- BALANCE and BRIGHT Trials: The company provided an update on the enrollment status for its BALANCE and BRIGHT phase III clinical trials, though specific enrollment numbers were not detailed in the filing text.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance, management commentary on future financial performance, or specific risk factors beyond the inherent uncertainties of clinical development. The primary focus is the operational progress of the phase III program.
Investor Verification Checklist
- Verify the specific enrollment numbers and timelines for the BALANCE and BRIGHT trials referenced in the attached press release (Exhibit 99.1).
- Review the full text of the press release to understand the implications of the BRIDGE trial completion on the expected data readout timeline.
- Check subsequent filings for any updates on the financial impact of these clinical milestones or changes in cash burn rate.